Aspire-Lakewood Holdings, Inc. (ASBPW)
Aspire Biopharma Holdings, Inc. operates as a biotechnology enterprise primarily focused on innovative diagnostic approaches and molecular analysis. The company's core mission involves engineering remarkably precise testing tools for the identification of various illnesses, utilizing breakthroughs in genetic and biochemical science to serve the needs of the healthcare and life science sectors.
Sector: Pharmaceutical Preparations
Industry: Medical - Pharmaceuticals
Aspire Biopharma Holdings, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 1.40M shares outstanding
USAspire Biopharma Holdings, Inc. is an emerging pharmaceutical enterprise dedicated to pioneering and commercializing innovative sublingual drug delivery systems within the United States.
Its flagship product, Instaprin, is an advanced sublingual aspirin formulation known for being soluble, pH neutral, and rapidly absorbed, making it effective for both cardiovascular emergencies and general pain management.
The company is diligently developing a diverse pipeline of orally dissolving formulations. This includes a melatonin-based sleep aid, essential vitamins (D, E, and K), testosterone, and semaglutide. Furthermore, Aspire Biopharma is extending its sublingual development efforts to various therapeutic areas, such as anti-nausea treatments, antipsychotic medications, erectile dysfunction drugs, and seizure control therapies, among others. They are also exploring caffeine products, including a formulation for a single-dose sublingual pre-workout supplement. Established in 2021, the firm's main operational base is situated in Estero, Florida.
Leadership
Kraig T. Higginson
Interim Chief Executive Officer, President & Executive Chairman of the Board
Ernest J. Scheidemann Jr.
Chief Financial Officer
Stephen E. Quesenberry
General Counsel & Corporate Secretary
Employees
2
Country
US
Sector
Healthcare
Website
aspirebiolabs.com
| Name | Shares | % | Source |
|---|---|---|---|
ADAGE CAPITAL PARTNERS GP, L.L.C. ASBPW | 1.1M | -- | 13F |
Saba Capital Management, L.P. ASBPW | 983.6K | -- | 13F |
LINDEN ADVISORS LP ASBPW | 900.0K | -- | 13F |
ARISTEIA CAPITAL, L.L.C. ASBPW | 681.5K | -- | 13F |
TORONTO DOMINION BANK ASBPW | 516.2K | -- | 13F |
Sculptor Capital LP ASBPW | 500.0K | -- | 13F |
Clear Street Group Inc. ASBPW | 330.7K | -- | 13F |
D. E. Shaw & Co., Inc. ASBPW | 200.0K | -- | 13F |
WOLVERINE ASSET MANAGEMENT LLC ASBPW | 197.1K | -- | 13F |
Verition Fund Management LLC ASBPW | 191.0K | -- | 13F |
based on 1.40M shares outstanding
US30d Avg
1.41K
60d Avg
6.53K
90d Avg
29.32K